Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma J P
INSERM U.143 Hôpital de Bicêtre, Paris, France.
Thromb Haemost. 1999 Nov;82(5):1382-5.
A protease present in plasma cleaves von Willebrand factor (vWF) at the peptide bond 842Tyr-843Met of the mature subunit. To quantify this vWF-cleaving protease activity in plasma we have developed a simple method based on the estimation by IRMA of the degradation of a constant amount of wild type recombinant vWF used as substrate, by serial dilutions of test plasma used as protease provider. vWFAg was estimated by two-site IRMA using as first coating antibody a monoclonal antibody (MoAb) whose epitope is localized on the C-terminal side of the cleavage site, and as second labeled antibody a pool of MoAbs specific for the N-terminal side. Because the proteolytic process leads to the progressive separation of the C- and N-terminal portions of the vWF subunit such an IRMA also shows a progressive apparent loss of vWFAg. In contrast, the levels of vWFAg estimated after proteolysis by regular IRMA remained essentially constant. Results obtained with this new method were compared with the analysis by SDS-agarose gel electrophoresis of the multimeric pattern of proteolyzed WT-rvWF and no significant difference was noted testing a series of 28 plasmas. As compared with normal pooled plasma, 14 normal individuals and 13 patients with various types of vWD had normal levels of protease activity (44-178%) by both methods. The validity of the method was confirmed by showing a lack of detectable protease activity in a patient with chronic relapsing thrombotic thrombocytopenic purpura. In conclusion our method appears as a useful tool for the quantification of the vWF-cleaving protease activity in plasma. Its sensitivity and specificity are similar to those of SDS-gel electrophoresis. However, this new IRMA has the major advantages of being much simpler and faster, and open to most research laboratories in the field.
血浆中存在的一种蛋白酶可在成熟亚基的肽键842Tyr - 843Met处切割血管性血友病因子(vWF)。为了定量血浆中这种vWF切割蛋白酶的活性,我们开发了一种简单的方法,该方法基于通过免疫放射分析(IRMA)对作为底物的恒定数量野生型重组vWF的降解进行估计,通过将用作蛋白酶来源的测试血浆进行系列稀释来实现。使用一种表位位于切割位点C端的单克隆抗体(MoAb)作为第一包被抗体,以及一组对N端特异的MoAb作为第二标记抗体,通过双位点IRMA估计vWFAg。由于蛋白水解过程导致vWF亚基的C端和N端部分逐渐分离,这样的IRMA也显示出vWFAg的逐渐明显丢失。相比之下,通过常规IRMA在蛋白水解后估计的vWFAg水平基本保持恒定。用这种新方法获得的结果与通过SDS - 琼脂糖凝胶电泳分析蛋白水解后的野生型重组vWF(WT - rvWF)的多聚体模式进行了比较,在测试一系列28份血浆时未发现显著差异。与正常混合血浆相比,14名正常个体和13名患有各种类型血管性血友病(vWD)的患者通过两种方法测得的蛋白酶活性水平均正常(44 - 178%)。通过显示一名慢性复发性血栓性血小板减少性紫癜患者缺乏可检测到的蛋白酶活性,证实了该方法的有效性。总之,我们的方法似乎是定量血浆中vWF切割蛋白酶活性的有用工具。其灵敏度和特异性与SDS - 凝胶电泳相似。然而,这种新的IRMA具有更简单、更快的主要优点,并且该领域的大多数研究实验室都可以使用。